annual cash & cash equivalents:
$392.10M+$196.29M(+100.25%)Summary
- As of today (July 1, 2025), OCUL annual cash & cash equivalents is $392.10 million, with the most recent change of +$196.29 million (+100.25%) on December 31, 2024.
- During the last 3 years, OCUL annual cash & cash equivalents has risen by +$227.94 million (+138.85%).
- OCUL annual cash & cash equivalents is now at all-time high.
Performance
OCUL Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$349.68M-$42.42M(-10.82%)Summary
- As of today (July 1, 2025), OCUL quarterly cash & cash equivalents is $349.68 million, with the most recent change of -$42.42 million (-10.82%) on March 31, 2025.
- Over the past year, OCUL quarterly cash & cash equivalents has dropped by -$133.21 million (-27.59%).
- OCUL quarterly cash & cash equivalents is now -27.59% below its all-time high of $482.89 million, reached on March 31, 2024.
Performance
OCUL quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
OCUL Cash and cash equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +100.3% | -27.6% |
3 y3 years | +138.8% | +140.5% |
5 y5 years | +620.3% | +626.2% |
OCUL Cash and cash equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +283.3% | -27.6% | +425.0% |
5 y | 5-year | at high | +620.3% | -27.6% | +425.0% |
alltime | all time | at high | +2139.9% | -27.6% | +2692.3% |
OCUL Cash and cash equivalents History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $349.68M(-10.8%) |
Dec 2024 | $392.10M(+100.2%) | $392.10M(-8.2%) |
Sep 2024 | - | $427.22M(-7.1%) |
Jun 2024 | - | $459.69M(-4.8%) |
Mar 2024 | - | $482.89M(+146.6%) |
Dec 2023 | $195.81M(+91.4%) | $195.81M(+77.1%) |
Sep 2023 | - | $110.55M(+66.0%) |
Jun 2023 | - | $66.61M(-15.7%) |
Mar 2023 | - | $79.03M(-22.8%) |
Dec 2022 | $102.30M(-37.7%) | $102.30M(-15.4%) |
Sep 2022 | - | $120.95M(-10.1%) |
Jun 2022 | - | $134.54M(-7.5%) |
Mar 2022 | - | $145.42M(-11.4%) |
Dec 2021 | $164.16M(-28.0%) | $164.16M(-8.4%) |
Sep 2021 | - | $179.28M(-6.6%) |
Jun 2021 | - | $191.86M(-8.4%) |
Mar 2021 | - | $209.38M(-8.2%) |
Dec 2020 | $228.06M(+318.9%) | $228.06M(+222.8%) |
Sep 2020 | - | $70.64M(-16.2%) |
Jun 2020 | - | $84.29M(+75.1%) |
Mar 2020 | - | $48.15M(-11.5%) |
Dec 2019 | $54.44M | $54.44M(-16.8%) |
Sep 2019 | - | $65.41M(+5.9%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2019 | - | $61.77M(-19.0%) |
Mar 2019 | - | $76.25M(+41.0%) |
Dec 2018 | $54.06M(+30.2%) | $54.06M(-4.9%) |
Sep 2018 | - | $56.86M(+0.0%) |
Jun 2018 | - | $56.83M(-9.7%) |
Mar 2018 | - | $62.91M(+51.5%) |
Dec 2017 | $41.54M(+26.1%) | $41.54M(-18.8%) |
Sep 2017 | - | $51.16M(-18.8%) |
Jun 2017 | - | $63.05M(+15.3%) |
Mar 2017 | - | $54.68M(+66.0%) |
Dec 2016 | $32.94M(+7.0%) | $32.94M(-36.9%) |
Sep 2016 | - | $52.23M(+8.4%) |
Jun 2016 | - | $48.17M(+4.2%) |
Mar 2016 | - | $46.21M(+50.1%) |
Dec 2015 | $30.78M(-17.7%) | $30.78M(-25.3%) |
Sep 2015 | - | $41.20M(-47.6%) |
Jun 2015 | - | $78.69M(+528.3%) |
Mar 2015 | - | $12.52M(-66.5%) |
Dec 2014 | $37.39M(+113.6%) | $37.39M(-53.8%) |
Sep 2014 | - | $80.89M(+305.6%) |
Jun 2014 | - | $19.94M(+56.4%) |
Mar 2014 | - | $12.75M(-27.2%) |
Dec 2013 | $17.50M(-26.6%) | $17.50M |
Dec 2012 | $23.85M | - |
FAQ
- What is Ocular Therapeutix annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ocular Therapeutix?
- What is Ocular Therapeutix annual cash & cash equivalents year-on-year change?
- What is Ocular Therapeutix quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Ocular Therapeutix?
- What is Ocular Therapeutix quarterly cash & cash equivalents year-on-year change?
What is Ocular Therapeutix annual cash & cash equivalents?
The current annual cash & cash equivalents of OCUL is $392.10M
What is the all time high annual cash & cash equivalents for Ocular Therapeutix?
Ocular Therapeutix all-time high annual cash & cash equivalents is $392.10M
What is Ocular Therapeutix annual cash & cash equivalents year-on-year change?
Over the past year, OCUL annual cash & cash equivalents has changed by +$196.29M (+100.25%)
What is Ocular Therapeutix quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of OCUL is $349.68M
What is the all time high quarterly cash & cash equivalents for Ocular Therapeutix?
Ocular Therapeutix all-time high quarterly cash & cash equivalents is $482.89M
What is Ocular Therapeutix quarterly cash & cash equivalents year-on-year change?
Over the past year, OCUL quarterly cash & cash equivalents has changed by -$133.21M (-27.59%)